Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders
Open Access
- 18 February 2008
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 21 (6), 605-608
- https://doi.org/10.1111/j.1432-2277.2008.00655.x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disordersLaboratory Investigation, 2007
- Sirolimus-Induced Remission of Posttransplantation Lymphoproliferative DisorderAmerican Journal of Kidney Diseases, 2006
- Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative DisordersJournal of Clinical Oncology, 2005
- Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimusNephrology Dialysis Transplantation, 2005
- Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2004
- Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma*Pediatric Transplantation, 2004
- World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997Journal of Clinical Oncology, 1999